Ginsenoside Rh2 Suppresses Breast Cancer Cell Proliferation by Epigenetically Regulating the Long Noncoding RNA C3orf67-AS1.

In this study, we report a novel long noncoding RNA, C3orf67-AS1, which was identified as being hypermethylated at a CpG site of the promoter by Rh2 in MCF-7 cancer cells. Rh2-induced hypermethylation was responsible for the lower gene expression; the expression was recovered following treatment with a methyltransferase inhibitor, 5-aza-2'-deoxycytidine. When C3orf67-AS1 was downregulated by a siRNA, the cell growth rate was decreased, demonstrating the RNA's oncogenic activity. Accordingly, breast cancer patients showed a lower methylation and higher expression level of C3orf67-AS1. Within 800 kb flanking C3orf67-AS1 on the chromosome, eight genes were found, and four genes including C3orf67 (the sense strand gene of C3orf67-AS1) were downregulated by Rh2. In particular, C3orf67 was downregulated when C3orf67-AS1 was suppressed by a siRNA; however, the expression of C3orf67-AS1 was not affected by C3orf67. Taken together, this study identifies a novel noncoding RNA, C3orf67-AS1, of which the expression could be suppressed by Rh2 via promoter methylation, thereby mediating the anti-proliferative effect of the ginsenoside. PMID: 31645124 [PubMed - as supplied by publisher]
Source: The American Journal of Chinese Medicine - Category: Complementary Medicine Authors: Tags: Am J Chin Med Source Type: research

Related Links:

Authors: Wang J, Zhang Y, Lu X, Xi C, Yu K, Gao R, Bi K Abstract Background: Idiopathic granulomatous mastitis (IGM) can clinically and radiographically mimic an abscess or breast cancer. Although IGM is benign, it can cause the breast skin to appear "riddled with holes" and can even result in the loss of the breast. The optimal treatment has not been established. Methods: We retrospectively studied the medical records of 200 patients with IGM who were treated for skin rupture from June 2015 to June 2017 in our institute. The patients' treatment modalities (including surgery after steroid therapy and ster...
Source: Journal of Investigative Surgery - Category: Surgery Tags: J Invest Surg Source Type: research
[This Day] Martins Ifijeh chronicles the life of a young ambitious Nigerian woman who was diagnosed with breast cancer, but due to ignorance and high cost of treatment, opted for herbal treatment in Jos, as against orthodox treatment, which then worsened her condition. She was however lucky to retrace her steps on time, and she is presently accessing proper healthcare in Abuja
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
[This Day] Abuja -Over 5,000 persons have benefited from diabetes, hypertension, cervical and breast cancer free screening, which was facilitated by MITEDA Wellness Initiative, a nongovernmental organisation and in collaboration with the Lagos State government.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Metastatic invasive lobular carcinoma (mILC) may masquerade as primary diffuse gastric adenocarcinoma (PDGA) by demonstrating significant clinical and pathologic overlap. Accurate distinction is of therapeutic and prognostic significance. On the basis of anecdotal cases of mILC that lacked estrogen receptor and/or GATA3 expression, we analyzed the cytoarchitectural features of 28 mILC and 44 PDGA specimens obtained from women to assess features that would help in this distinction and prompt ancillary work-up. In addition to performing an interobserver agreement analysis among 3 pathologists, we also evaluated SATB2 express...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
There is new hope in the battle against breast cancer. A promising new drug targets tumors with remarkable precision. Dr. Jon LaPook reports.
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
Women aged ≥65 years have the highest age-specific rates of breast cancer incidence in the UK. However, national audit results demonstrate that the rates of post-mastectomy breast reconstruction offered to and performed in this age group are considerably lower than in younger women1. This discrepancy may ari se from unsubstantiated concerns over greater medical and surgical risk in older patients2. In the present study, the first of its kind in the UK, we sought to evaluate potential differences in postoperative complications following autologous breast reconstruction between young and older patient pop ulations.
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - Category: Cosmetic Surgery Authors: Source Type: research
Publication date: 10 December 2019Source: Cell Reports, Volume 29, Issue 11Author(s): Yuanpei Xu, Yingcheng Wu, Siliang Zhang, Panpan Ma, Xinxin Jin, Zhou Wang, Min Yao, Erhao Zhang, Baorui Tao, Yongwei Qin, Hao Chen, Aifen Liu, Miaomiao Chen, Mingbing Xiao, Cuihua Lu, Renfang Mao, Yihui FanSummaryPD-L1 and PD-L2 are important targets for immune checkpoint blockade, but how tumor cells achieve their expression remains to be addressed. Here, we find that PD-L1 and PD-L2 are co-expressed in cancer cell lines and tissues across different cancer types. In breast cancer, MDA-MB-231 and SUM-159 cells show high expression of both...
Source: Cell Reports - Category: Cytology Source Type: research
Publication date: 10 December 2019Source: Cell Reports, Volume 29, Issue 11Author(s): William W. Feng, Owen Wilkins, Scott Bang, Matthew Ung, Jiaqi Li, Jennifer An, Carmen del Genio, Kaleigh Canfield, James DiRenzo, Wendy Wells, Arti Gaur, R. Brooks Robey, Jessie Yanxiang Guo, Ryan L. Powles, Christos Sotiriou, Lajos Pusztai, Maria Febbraio, Chao Cheng, William B. Kinlaw, Manabu KurokawaSummaryAlthough it is established that fatty acid (FA) synthesis supports anabolic growth in cancer, the role of exogenous FA uptake remains elusive. Here we show that, during acquisition of resistance to HER2 inhibition, metabolic rewiring...
Source: Cell Reports - Category: Cytology Source Type: research
A new analysis some 6 years after randomization continues to support dual HER2 blockade plus chemotherapy for HER2-positive early breast cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common types of the disease.The findings also show the combination treatment is beneficial at the time of recurrence and should become a first-line option in postmenopausal women with HR+/HER2- advanced breast cancer.The study was published today in the New England Journal of Medicine and presented earlier this year at the European Society for Medical Oncology Congress in...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Complementary Medicine | Genetics | Ginseng | Study